Blog
RSS FeedPosted by Michael Wonder on 18 Jun 2020
Clinical trial costs to develop a new drug may actually be rather modest — or so one study suggests
18 June 2020 - For years, the pharmaceutical industry has maintained that the costs to develop medicines accounts for rising ...
Posted by Michael Wonder on 18 Jun 2020
Linnaeus Therapeutics granted U.S. FDA fast track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on anti-PD-1/L1 therapy
18 June 2020 - Company Conducting Ongoing Phase 1/2 Study of LNS8801. ...
Posted by Michael Wonder on 18 Jun 2020
FDA granted accelerated approval to tazemetostat for follicular lymphoma
18 June 2020 - Today the Food and Drug Administration granted accelerated approval to tazemetostat (Tazverik, Epizyme), an EZH2 inhibitor, ...
Posted by Michael Wonder on 18 Jun 2020
FDA approves first therapy for rare disease that causes low phosphate blood levels, bone softening
18 June 2020 - Today, the U.S. Food and Drug Administration approved Crysvita (burosumab-twza) injection to treat patients age two and ...
Posted by Michael Wonder on 18 Jun 2020
TG Therapeutics completes rolling submission of new drug application to the U.S. FDA for umbralisib as a treatment for patients with previously treated marginal zone lymphoma or follicular lymphoma
17 June 2020 - TG Therapeutics today announced the completion of the rolling submission of a new drug application to the ...
Posted by Michael Wonder on 18 Jun 2020
Chi-Med announces fruquintinib granted U.S. FDA fast track designation for metastatic colorectal cancer
18 June 2020 - Hutchison China MediTech today announces that the U.S. FDA has granted fast track designation for the development ...
Posted by Michael Wonder on 17 Jun 2020
Identifying the risks of unproven regenerative medicine therapies
17 June 2020 - In the middle of the coronavirus disease 2019 public health response, many priorities are currently competing for ...
Posted by Michael Wonder on 17 Jun 2020
Ipsen receives FDA fast track designation for liposomal irinotecan (Onivyde) as a first-line combination treatment for metastatic pancreatic cancer
17 June 2020 - Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at ...
Posted by Michael Wonder on 17 Jun 2020
FDA approves pembrolizumab for adults and children with TMB-H solid tumours
17 June 2020 - On 16 June 2020, the FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment ...
Posted by Michael Wonder on 17 Jun 2020
A mad scramble to stock millions of malaria pills, likely for nothing
16 June 2020 - Before the F.D.A. withdrew its waiver to stockpile the drugs as coronavirus treatments, the Trump administration had ...
Posted by Michael Wonder on 17 Jun 2020
An ‘America first’ pharma supply chain sounds good. But it won’t work.
17 June 2020 - With a stroke of the president’s Executive Order pen, the Trump administration awarded a $354 million, ...
Posted by Michael Wonder on 17 Jun 2020
Most coronavirus tests cost about $100. Why did one cost $2,315?
16 June 2020 - U.S. health care prices are unregulated, opaque and unpredictable. When Congress required insurers to cover COVID-19 testing, ...
Posted by Michael Wonder on 17 Jun 2020
Regulators discuss accelerated approvals, Project Orbis at DIA
16 June 2020 - Regulators from the US FDA, European Medicines Agency and Health Canada gave their perspectives on different ...
Posted by Michael Wonder on 17 Jun 2020
Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
17 June 2020 - FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active ...
Posted by Michael Wonder on 16 Jun 2020
FDA approves first treatment for adult onset Still’s disease, a severe and rare disease
16 June 2020 - The U.S. Food and Drug Administration today approved Ilaris (canakinumab) injection for the treatment of active Still’s ...